PCN8: COST-UTILITY ANALYSIS OF SEVERAL SECOND-LINE CHEMOTHERAPY SCHEMES FOR PATIENTS WITH METASTATIC BREAST CANCER

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Second Line ◽

Utility Analysis ◽

A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer

PharmacoEconomics ◽

10.2165/00019053-199610050-00008 ◽

1996 ◽

Vol 10 (5) ◽

pp. 504-521 ◽

Cited By ~ 57

Author(s):

Robert Launois ◽

Jeanne Reboul-Marty ◽

Bernadette Henry ◽

Jacques Bonneterre

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Second Line ◽

Utility Analysis ◽

A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer

Anti-Cancer Drugs ◽

10.1097/00001813-200107000-00007 ◽

2001 ◽

Vol 12 (6) ◽

pp. 533-540 ◽

Cited By ~ 10

Author(s):

N Li ◽

M van Agthoven ◽

PHB Willemse ◽

CA Uyl-de Groot

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Second Line ◽

Utility Analysis ◽

Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study)

10.1158/1538-7445.sabcs20-ps13-31 ◽

2021 ◽

Author(s):

Yuri Fujimoto ◽

Yuichiro Kikawa ◽

Takeshi Kotake ◽

Shigeru Tsuyuki ◽

Sachiko Takahara ◽

...

Keyword(s):

Breast Cancer ◽

Observational Study ◽

Prospective Observational Study ◽

Metastatic Breast ◽

Second Line ◽

230 A Phase II Study of Pegylated Liposomal Doxorubicin Combined with Cyclophosphamide / 5-fluorouracil as Second Line Chemotherapy in Patients with Metastatic Breast Cancer Who Failed Previous Taxane-based Treatment

European Journal of Cancer ◽

10.1016/s0959-8049(12)70298-8 ◽

2012 ◽

Vol 48 ◽

pp. S109-S110

Author(s):

H.K. Chang ◽

Y.C. Lin ◽

K.M. Rau ◽

Y.Y. Chen ◽

K.D. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Second Line ◽

Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Value in Health ◽

10.1016/j.jval.2014.08.2289 ◽

2014 ◽

Vol 17 (7) ◽

pp. A637

Author(s):

I. Krysanov ◽

V. Krysanova

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Effectiveness Analysis ◽

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-007-0259-0 ◽

2007 ◽

Vol 134 (2) ◽

pp. 125-135 ◽

Cited By ~ 9

Author(s):

Martina Baur ◽

Allan T. van Oosterom ◽

Véronique Diéras ◽

Michele Tubiana-Hulin ◽

R. Charles Coombes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Second Line ◽

Abstract P1-10-05: A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs14-p1-10-05 ◽

2015 ◽

Author(s):

George Dranitsaris ◽

Bo Yu ◽

Jennifer King ◽

Adams Zhang ◽

Satyn Kaura ◽

...

Keyword(s):

Breast Cancer ◽

Health Care ◽

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis

A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e13059 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e13059-e13059 ◽

Cited By ~ 2

Author(s):

Mitsuhiko Iwamoto ◽

Kosei Kimura ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Patient Reported ◽

255 A Spanish Cost-utility Analysis of Nab-paclitaxel Compared to Conventional Paclitaxel Monotherapy for Pretreated Metastatic Breast Cancer: Results From the COSTABRAX Study

European Journal of Cancer ◽

10.1016/s0959-8049(12)70322-2 ◽

2012 ◽

Vol 48 ◽

pp. S117

Author(s):

E. Alba ◽

E. Ciruelos ◽

R. Lopez ◽

J.M. López Vega ◽

A. Lluch ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis

Abstract P6-11-03: Beyond the Second Line Chemotherapy in Metastatic Breast Cancer: When Stop the Treatment between Science and Conscience

10.1158/0008-5472.sabcs10-p6-11-03 ◽

2010 ◽

Cited By ~ 1

Author(s):

G Bernardo ◽

R Palumbo ◽

G Poggi ◽

A Bernardo ◽

C Teragni ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Second Line ◽